|
HBS Ag seroclearance and seroconversion time in patients with chronic hepatitis B infection
|
Jila Masrour-Roudsari    , Mohammadreza Hasanjani-Roushan , Yousef Yahyapour , Rahim Barari-Savadkoohi , Ali Bijani , Farzin Sadeghi , Mousa Mohammadnia-Afroozi |
| Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran , uyahyapoor@yahoo.com |
|
|
Abstract: (3879 Views) |
Background: Hepatitis B Surface antigen (HBsAg) seroclearance and seroconversion (development of antibodies against HBsAg) can increases the survival of Chronic hepatitis B (CHB) patients. The aim of this study was to determine the percentage and timing of HBsAg seroclearance and seroconversion in patients with chronic hepatitis B infection.
Methods: 1026 patients with CHB infection who referred to a private clinic were included. These patients had been followed-up for an average of 15 years. The patients whose HBs Ag was cleared from the blood and remained negative until the end of follow-up were designated as HBs Ag serocleared and the patients whose HBs Ab was positive during follow-upwas designated as HBs Ag seroconverted. The time of seroclearance and seroconversion of patients was recorded. Liver function tests, alpha-fetoprotein (AFP) and Hepatitis B early antigen (HBe Ag) status were extracted from the patients’ medical records. Data were analysis with SPSS 17.
Results: The duration of follow-up was from 2 to 410 months and most patients were males (58.2%).
The survival rate of HBs Ag positivity after 5, 10 and 15 years were 95.6, 89.4 and 80.7%, and 98, 93.5 and 84.9% of patients had not yet developed anti-HBs antibodies after 5, 10 and 15 years, respectively. Age, gender and taking medication had no effect on HBs Ag clearance from the blood or anti-HBs production
Conclusion: The HBs Ag seroconversion is a rare occurrence, but the incidence of this may increase with time, age and drug consumption. Though there was no relationship in our patients
|
|
| Keywords: Chronic Hepatitis B, Seroclearance, Seroconversion, Hepatitis B Surface antigen |
|
|
Full-Text [PDF 228 kb]
(1034 Downloads)
|
Type of Study: Original Article |
Subject:
Infectious Diseases
Received: 2020/02/12 | Accepted: 2020/04/19 | Published: 2020/04/22
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
